Investigational drug · Phase 3
dabocemagene autoficel
Also called: FCX-007, see below for FCX-007 description
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Recessive Dystrophic Epidermolysis Bullosa.
Phase 3Last checked: Nov 20, 2026Latest source record: Mar 18, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "dabocemagene autoficel"
First trial start
2020
Jun 9, 2020
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "dabocemagene autoficel", any sponsor or status.
Conditions studied
As listed on its trial records.
- Recessive Dystrophic Epidermolysis Bullosa
Approved drugs for the same conditions: Dermatology
Largest trials
Live from ClinicalTrials.gov: studies naming "dabocemagene autoficel" as an intervention, largest first.
- Evaluation of D-Fi for the Treatment of Wounds Due to DEBPivotal-lookingActive, not recruiting
Castle Creek Biosciences, LLC.Industry
NCT06892639 · 32 participants (planned) · Start Mar 27, 2025 · Primary completion Sep 2027
Drug: D-Fi · For: Dystrophic Epidermolysis Bullosa
Sites: Redwood City, California; Santa Margarita, California; Aurora, Colorado · 4 sites in all
- A Study of FCX-007 for Recessive Dystrophic Epidermolysis BullosaPivotal-lookingActive, not recruiting
Castle Creek Biosciences, LLC.Industry
NCT04213261 · 6 participants · Start Jun 9, 2020 · Primary completion Jan 17, 2023
Drug: FCX-007 (dabocemagene autoficel; see below for FCX-007 description) · For: Recessive Dystrophic Epidermolysis Bullosa
Sites: Stanford, California; Aurora, Colorado; Jacksonville, Florida · 5 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Recessive Dystrophic Epidermolysis Bullosa
- KB803Phase 31 trial
Krystal Biotech, Inc. · Dystrophic Epidermolysis Bullosa, DEB - Dystrophic Epidermolysis Bullosa, Recessive Dystrophic Epidermolysis Bullosa
- pz-celEB-101 Surgical application of RDEB woundsPhase 31 trial
Abeona Therapeutics, Inc · Epidermolysis Bullosa, Recessive Dystrophic Epidermolysis Bullosa, RDEB
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.